Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis

Biomaterials

Volumn 77, Issue , 2016, Pages 87-97

  Liao, Wenbin ^a   Pham, Victor ^a,b   Liu, Linan ^a   Riazifar, Milad ^a   Pone, Egest J ^a   Zhang, Shirley Xian ^a   Ma, Fengxia ^a,c   Lu, Mengrou ^a   Walsh, Craig M ^d   Zhao, Weian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d Irvine   (United States)

Author keywords

Cell homing; EAE; Mesenchymal stem cell; MRNA transfection; MSC; Multiple sclerosis

Indexed keywords

CELLS; CYTOLOGY; ENDOTHELIAL CELLS; FLOWCHARTING; LIGANDS; LYMPHOCYTES; MAMMALS; MOLECULAR BIOLOGY; STEM CELLS;

EAE; MESENCHYMAL STEM CELL; MRNA TRANSFECTION; MSC; MULTIPLE SCLEROSIS;

CELL CULTURE;

INTERLEUKIN 10; MESSENGER RNA; P SELECTIN GLYCOPROTEIN LIGAND 1; SIALYL LEWIS X ANTIGEN; CD15 ANTIGEN; HYBRID PROTEIN; IL10 PROTEIN, HUMAN; MEMBRANE PROTEIN; N ACETYLNEURAMINIC ACID; P-SELECTIN LIGAND PROTEIN;

ADHERENT CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SPINAL CORD BARRIER; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BRAIN BLOOD FLOW; BRAIN CAPILLARY ENDOTHELIAL CELL; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL HOMING; CELL MIGRATION ASSAY; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE ROLLING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; MYELINATION; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD BLOOD FLOW; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; WHITE MATTER; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; C57BL MOUSE; CELL MOTION; COCULTURE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE VECTOR; GENETICS; HL-60 CELL LINE; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; METABOLISM; MYELIN SHEATH; PATHOLOGY; PHYSIOLOGY; SPINAL CORD;

ANIMALS; ANTIGENS, CD15; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL MOVEMENT; COCULTURE TECHNIQUES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GENETIC VECTORS; HL-60 CELLS; HUMANS; INTERLEUKIN-10; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MYELIN SHEATH; N-ACETYLNEURAMINIC ACID; ORGAN SPECIFICITY; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SPINAL CORD; TRANSFECTION;

EID: 84949255414     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.11.005     Document Type: Article

References (60)

1. G. Adelman, S.G. Rane, K.F. Villa, The cost burden of multiple sclerosis in the United States: a systematic review of the literature, J. Med. Econ. 16:639-647.
2. A. Uccelli, A. Laroni, M.S. Freedman, Mesenchymal stem cells as treatment for MS - progress to date, Mult. Scler. - Houndmills Basingstoke Engl. 19:515-519.
3. S.P. Liu, R.H. Fu, S.J. Huang, et al., Stem cell applications in regenerative medicine for neurological disorders, Cell Transplant. 22:631-637.
4. T. Ben-Hur, Cell therapy for multiple sclerosis, Neurotherapeutics. 8:625-642.
5. T. Gharibi , M. Ahmadi, N. Seyfizadeh, et al., Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of Multiple Sclerosis, Cell. Immunol. 293:113-121.
6. M.A. Eckert, Q. Vu, K. Xie, et al., Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke, J. Cereb. Blood Flow. Metab. 33:1322-1334.
7. S. Llufriu, M. Sepulveda, Y. Blanco, et al., Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis, PLoS One. 9:e113936.
8. Q. Vu, K. Xie, M. Eckert, et al., Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke, Neurology 82:1277-1286.
9. W. Peng, J. Sun, C. Sheng, et al., Systematic review and meta-analysis of efficacy of mesenchymal stem cells on locomotor recovery in animal models of traumatic brain injury, Stem Cell Res. Ther. 6:47.
10. T.R. Doeppner, D.M. Hermann. Stem cell-based treatments against stroke: observations from human proof-of-concept studies and considerations regarding clinical applicability, Front. Cell. Neurosci. 8:357.
11. O.I. Eseonu, C. De Bari, Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis, Rheumatol. Oxf. Engl. 54:210-218.
12. I.A. Droujinine, M.A. Eckert, W. Zhao, To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells, Oncotarget 4:651-664.
13. Kidd S., Spaeth E., Dembinski J.L., et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells Dayt. Ohio 2009, 27:2614-2623.
14. Karp J.M., Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4:206-216.
15. D. Masopust, J.M. Schenkel, The integration of T cell migration, differentiation and function, Nat. Rev. 13:309-320.
16. Ley K., Kansas G.S. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat. Rev. 2004, 4:325-335.
17. Ruster B., Gottig S., Ludwig R.J., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
18. Segers V.F., Van Riet I., Andries L.J., et al. Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am. J. Physiol. 2006, 290:H1370-H1377.
19. Steingen C., Brenig F., Baumgartner L., et al. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J. Mol. Cell. Cardiol. 2008, 44:1072-1084.
20. Schmidt A., Ladage D., Steingen C., et al. Mesenchymal stem cells transmigrate over the endothelial barrier. Eur. J. Cell Biol. 2006, 85:1179-1188.
21. T. Matsushita, T. Kibayashi, T. Katayama, et al., Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps, Neurosci. Lett. 502:41-45.
22. Liu L., Eckert M.A., Riazifar H., et al. From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier?. Stem Cells Int. 2013, 435093.
23. G.S. Teo, Z. Yang, C.V. Carman, et al., Intravital imaging of mesenchymal stem cell trafficking and association with platelets and neutrophils, Stem Cells Dayt. Ohio 33:265-277.
24. Sackstein R., Merzaban J.S., Cain D.W., et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 2008, 14:181-187.
25. D. Sarkar, J.A. Spencer, J.A. Phillips, et al., Engineered cell homing, Blood. 118:e184-191.
26. R. Sridharan, J.M. Karp, W. Zhao. Bioengineering tools to elucidate and control the fate of transplanted stem cells, Biochem. Soc. Trans. 42:679-687.
27. M.E. Bernardo, W.E. Fibbe, Mesenchymal stromal cells: sensors and switchers of inflammation, Cell Stem Cell. 13:392-402.
28. O. Levy, W. Zhao, L.J. Mortensen, et al., mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation, Blood. 122:e23-32.
29. U. Sahin, K. Kariko, O. Tureci, mRNA-based therapeutics-developing a new class of drugs, Nat. Rev. Drug Discov. 13:759-780.
30. Wiehe J.M., Ponsaerts P., Rojewski M.T., et al. mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J. Cell. Mol. Med. 2007, 11:521-530.
31. E. Pierson, S.B. Simmons, L. Castelli, et al., Mechanisms regulating regional localization of inflammation during CNS autoimmunity, Immunol. Rev. 248:205-215.
32. N. Hermann-Kleiter, M. Meisel, F. Fresser, et al., Nuclear orphan receptor NR2F6 directly antagonizes NFAT and RORgammat binding to the Il17a promoter, J. Autoimmun. 39:428-440.
33. Luster A.D., Alon R., von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005, 6:1182-1190.
34. Xu H., Manivannan A., Crane I., et al. Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. Blood 2008, 112:1166-1174.
35. Ley K., Bullard D.C., Arbones M.L., et al. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. J. Exp. Med. 1995, 181:669-675.
36. Varki A. Selectin ligands. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:7390-7397.
37. M. Guan, W. Yao, R. Liu, et al., Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass, Nat. Med. 18:456-462.
38. J. Huang, Z. Zhang, J. Guo, et al., Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium, Circ. Res. 106:1753-1762.
39. X. Yu, D. Chen, Y. Zhang, et al., Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke, J. Neurol. Sci. 316:141-149.
40. Kariko K., Buckstein M., Ni H., et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175.
41. Kariko K., Muramatsu H., Welsh F.A., et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008, 16:1833-1840.
42. L. Warren, P.D. Manos, T. Ahfeldt, et al., Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA, Cell Stem Cell 7:618-630.
43. M. Angel, M.F. Yanik, Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins, PLoS One. 5:e11756.
44. M.S. Kormann, G. Hasenpusch, M.K. Aneja, et al., Expression of therapeutic proteins after delivery of chemically modified mRNA in mice, Nat. Biotechnol. 29:154-157.
45. K. Kariko, H. Muramatsu, J.M. Keller, et al., Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin, Mol. Ther. 20:948-953.
46. Carvalho-Tavares J., Hickey M.J., Hutchison J., et al. A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ. Res. 2000, 87:1141-1148.
47. K.C. Rustad, G.C. Gurtner, Mesenchymal Stem Cells Home to Sites of Injury and Inflammation, Adv. Wound Care. 1:147-152.
48. Alt C., Duvefelt K., Franzen B., et al. Gene and protein expression profiling of the microvascular compartment in experimental autoimmune encephalomyelitis in C57Bl/6 and SJL mice. Brain Pathol. - Zurich Switz. 2005, 15:1-16.
49. C.S. Constantinescu, N. Farooqi, K. O'Brien, et al., Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS), Br. J. Pharmacol. 164:1079-1106.
50. J.M. Fletcher, S.J. Lalor, C.M. Sweeney, et al., T cells in multiple sclerosis and experimental autoimmune encephalomyelitis, Clin. Exp. Immunol. 162:1-11.
51. Sonobe Y., Jin S., Wang J., et al. Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Tohoku J. Exp. Med. 2007, 213:329-339.
52. Spaeth E., Klopp A., Dembinski J., et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008, 15:730-738.
53. da Silva Meirelles L., Caplan A.I., Nardi N.B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells Dayt. Ohio 2008, 26:2287-2299.
54. Piccio L., Rossi B., Scarpini E., et al. Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J. Immunol. 2002, 168:1940-1949.
55. Kerfoot S.M., Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169:1000-1006.
56. Cheng Z., Ou L., Zhou X., et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther. 2008, 16:571-579.
57. Lee R.H., Pulin A.A., Seo M.J., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
58. L. von Bahr, I. Batsis, G. Moll, et al., Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation, Stem Cells Dayt. Ohio 30:1575-1578.
59. Stiehler M., Duch M., Mygind T., et al. Optimizing viral and non-viral gene transfer methods for genetic modification of porcine mesenchymal stem cells. Adv. Exp. Med. Biol. 2006, 585:31-48.
60. S.H. Ranganath, O. Levy, M.S. Inamdar, et al., Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease, Cell Stem Cell. 10:244-258.